These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

223 related items for PubMed ID: 25483483

  • 1. A population-weighted, condition-adjusted estimate of palivizumab efficacy in preventing RSV-related hospitalizations among US high-risk children.
    Ambrose CS, Chen X, Kumar VR.
    Hum Vaccin Immunother; 2014; 10(10):2785-8. PubMed ID: 25483483
    [Abstract] [Full Text] [Related]

  • 2. Serum palivizumab level is associated with decreased severity of respiratory syncytial virus disease in high-risk infants.
    Forbes ML, Kumar VR, Yogev R, Wu X, Robbie GJ, Ambrose CS.
    Hum Vaccin Immunother; 2014; 10(10):2789-94. PubMed ID: 25483663
    [Abstract] [Full Text] [Related]

  • 3. Cost-utility analysis of palivizumab for preventing respiratory syncytial virus in preterm neonates and infants in Colombia.
    Ordóñez JE, Huertas VM.
    BMC Infect Dis; 2024 Apr 19; 24(1):418. PubMed ID: 38641577
    [Abstract] [Full Text] [Related]

  • 4. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
    Pediatrics; 1998 Sep 19; 102(3 Pt 1):531-7. PubMed ID: 9738173
    [Abstract] [Full Text] [Related]

  • 5. Effectiveness and Safety of Palivizumab for the Prevention of Serious Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus: A Systematic Review.
    Gonzales T, Bergamasco A, Cristarella T, Goyer C, Wojdyla M, Oladapo A, Sawicky J, Yee J, Moride Y.
    Am J Perinatol; 2024 May 19; 41(S 01):e1107-e1115. PubMed ID: 36452969
    [Abstract] [Full Text] [Related]

  • 6. Palivizumab: a review of its use as prophylaxis for serious respiratory syncytial virus infection.
    Fenton C, Scott LJ, Plosker GL.
    Paediatr Drugs; 2004 May 19; 6(3):177-97. PubMed ID: 15170364
    [Abstract] [Full Text] [Related]

  • 7. Updated cost-effectiveness analysis of palivizumab (Synagis) for the prophylaxis of respiratory syncytial virus in infant populations in the UK.
    Narayan O, Bentley A, Mowbray K, Hermansson M, Pivonka D, Kemadjou EN, Belsey J.
    J Med Econ; 2020 Dec 19; 23(12):1640-1652. PubMed ID: 33107769
    [Abstract] [Full Text] [Related]

  • 8. Risk factors for hospitalisation due to respiratory syncytial virus infection in children receiving prophylactic palivizumab.
    Chida-Nagai A, Sato H, Sato I, Shiraishi M, Sasaki D, Izumi G, Yamazawa H, Cho K, Manabe A, Takeda A.
    Eur J Pediatr; 2022 Feb 19; 181(2):539-547. PubMed ID: 34417646
    [Abstract] [Full Text] [Related]

  • 9. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.
    American Academy of Pediatrics Committee on Infectious Diseases, American Academy of Pediatrics Bronchiolitis Guidelines Committee.
    Pediatrics; 2014 Aug 19; 134(2):e620-38. PubMed ID: 25070304
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and optimization of palivizumab injection regimens against respiratory syncytial virus infection.
    Gutfraind A, Galvani AP, Meyers LA.
    JAMA Pediatr; 2015 Apr 19; 169(4):341-8. PubMed ID: 25706618
    [Abstract] [Full Text] [Related]

  • 11. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
    Romero JR.
    Pediatr Infect Dis J; 2003 Feb 19; 22(2 Suppl):S46-54. PubMed ID: 12671452
    [Abstract] [Full Text] [Related]

  • 12. Effect of Prophylactic Palivizumab on Admission Due to Respiratory Syncytial Virus Infection in Former Very Low Birth Weight Infants with Bronchopulmonary Dysplasia.
    Han YM, Seo HJ, Choi SH, Jung YJ, Ahn SY, Yoo HS, Sung SI, Shim JW, Lee YK, Ko SY, Shin SM, Hwang JH, Lee JH, Choi BM, Kim ES, Jeon JH, Kim SS, Chang YS, Park WS.
    J Korean Med Sci; 2015 Jul 19; 30(7):924-31. PubMed ID: 26130956
    [Abstract] [Full Text] [Related]

  • 13. A prospective, open-label, non-comparative study of palivizumab prophylaxis in children at high risk of serious respiratory syncytial virus disease in the Russian Federation.
    Turti TV, Baibarina EN, Degtiareva EA, Keshishyan ES, Lobzin YV, Namazova-Вaranova LS, Prodeus AP, Gudkov KM, Kruglova AI, Schulz GA, Notario GF.
    BMC Res Notes; 2012 Sep 04; 5():484. PubMed ID: 22943074
    [Abstract] [Full Text] [Related]

  • 14. An epidemiological investigation of high-risk infants for Respiratory Syncytial Virus infections: a retrospective cohort study.
    Servadio M, Finocchietti M, Vassallo C, Cipelli R, Heiman F, Di Lucchio G, Oresta B, Addis A, Belleudi V.
    Ital J Pediatr; 2024 Mar 25; 50(1):56. PubMed ID: 38528568
    [Abstract] [Full Text] [Related]

  • 15. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn.
    Pediatrics; 1998 Nov 25; 102(5):1211-6. PubMed ID: 9794957
    [Abstract] [Full Text] [Related]

  • 16. Variation in clinical practice guidelines for use of palivizumab in preventing severe respiratory syncytial viral (RSV) disease in high-risk infants.
    Stiboy E, Chan M, Islam MS, Saravanos GL, Lui K, Jaffe A, Homaira N.
    Pediatr Pulmonol; 2023 Apr 25; 58(4):1210-1220. PubMed ID: 36748923
    [Abstract] [Full Text] [Related]

  • 17. Outcomes of Infants Receiving Palivizumab Prophylaxis for Respiratory Syncytial Virus in Canada and Italy: An International, Prospective Cohort Study.
    Manzoni P, Paes B, Lanctôt KL, Dall'Agnola A, Mitchell I, Calabrese S, Maule M, Girardi E, Harimoto T, Li A.
    Pediatr Infect Dis J; 2017 Jan 25; 36(1):2-8. PubMed ID: 27649365
    [Abstract] [Full Text] [Related]

  • 18. Partial palivizumab prophylaxis and increased risk of hospitalization due to respiratory syncytial virus in a Medicaid population: a retrospective cohort analysis.
    Krilov LR, Masaquel AS, Weiner LB, Smith DM, Wade SW, Mahadevia PJ.
    BMC Pediatr; 2014 Oct 13; 14():261. PubMed ID: 25308481
    [Abstract] [Full Text] [Related]

  • 19. A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis.
    Frogel MP, Stewart DL, Hoopes M, Fernandes AW, Mahadevia PJ.
    J Manag Care Pharm; 2010 Oct 13; 16(1):46-58. PubMed ID: 20131495
    [Abstract] [Full Text] [Related]

  • 20. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.
    Meissner HC, Long SS, American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn.
    Pediatrics; 2003 Dec 13; 112(6 Pt 1):1447-52. PubMed ID: 14654628
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.